



Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution[☆]



David W. Scharp^{a,*}, Piero Marchetti^{b,1}

^a Prodo Laboratories & Scharp-Lacy Research Institute, 32A Mauchly, Irvine, CA 92618, USA

^b Department of Endocrinology and Metabolism, Metabolic Unit, Cisanello Hospital, University of Pisa, Via Paradise 2, Pisa 56100, Italy

ARTICLE INFO

Available online 1 August 2013

Keywords:

Islets
Immuno-isolation
Encapsulation
Diabetes
Transplantation
Implantation
Macro-device
Micro-device
"Conformal coating"
"Minimum Volume Capsule"

ABSTRACT

Insulin therapy became a reality in 1921 dramatically saving lives of people with diabetes, but not protecting them from long-term complications. Clinically successful free islet implants began in 1989 but require life long immunosuppression. Several encapsulated islet approaches have been ongoing for over 30 years without defining a clinically relevant product. Macro-devices encapsulating islet mass in a single device have shown long-term success in large animals but human trials have been limited by critical challenges. Micro-capsules using alginate or similar hydrogels encapsulate individual islets with many hundreds of promising rodent results published, but a low incidence of successful translation to large animal and human results. Reduction of encapsulated islet mass for clinical transplantation is in progress. This review covers the status of both early and current studies including the presentation of corporate efforts involved. It concludes by defining the critical items requiring solution to enable a successful clinical diabetes therapy.

© 2013 Elsevier B.V. All rights reserved.

Contents

1.	Introduction	36
1.1.	Historic antecedents to islet encapsulation	36
1.1.1.	Diabetic antiquities	36
1.1.2.	Clinical diabetes prior to insulin	36
1.1.3.	Pancreatic tissue implants	37
1.1.4.	Fetal islet implants	37
1.1.5.	Immuno-privileged sites	37
1.1.6.	Islet implants	38
1.2.	Concerns for clinical islet encapsulation achieving clinical success	38
1.2.1.	Rodent results not translating to large animals and human needs	38
1.2.2.	Acute islet loss post-implant	39
1.2.3.	Requirement for immunosuppression	39
1.2.4.	Donor sensitization	39
1.2.5.	Insufficient islets for a clinical therapy	39
2.	Structural approaches for islet encapsulation	39
2.1.	Macro-devices	39
2.1.1.	Extravascular Diffusion Devices	39
2.1.2.	Intravascular Diffusion Devices	41
2.1.3.	Intravascular Ultrafiltration Devices	41

[☆] This review is part of the *Advanced Drug Delivery Reviews* theme issue on "Cell encapsulation and drug delivery".

* Corresponding author. Tel.: +1 949 727 1972.

E-mail addresses: dscharp@prodolabs.com (D.W. Scharp), piero.marchetti@med.unipi.it (P. Marchetti).

¹ Tel.: +39 050 995 110.

2.2.	Micro-devices	42
2.2.1.	Alginate based micro-capsules	42
2.2.2.	Other micro-capsule approaches	44
2.3.	Conformal coatings	45
2.3.1.	PEG coatings	45
2.4.	Nanoencapsulation or layer by layer approaches	53
2.4.1.	Layer of cells over surface of islets	54
3.	Host interactions	54
3.1.	Instant blood-mediated inflammatory reaction	54
3.2.	Immune protection	55
3.2.1.	Allografts	55
3.2.2.	Xenografts	55
4.	Insulin secretory dynamics from encapsulated islets	56
4.1.	Encapsulated islet function	56
4.2.	Long-Term Replacement Strategy	57
4.2.1.	All In/Biodegrade Out replacement	58
4.2.2.	All In/All Out replacement	58
4.2.3.	Flush/Reload replacement	58
5.	History of corporate funding in islet encapsulation	58
5.1.	Descriptions of corporate investigations	58
5.2.	Summary of corporate activities in islet encapsulation	59
5.2.1.	Hollow Fiber Technology – Group of Amicon, WR Grace, Grace Biomedical, and Circe Biomedical	60
5.2.2.	Hollow Fiber Technology – Cytotherapeutics	61
5.2.3.	Supported flat sheet device – Group of Baxter Health Care, Neocrin, Theracyte, Viacyte, and Betalogics	61
5.2.4.	Minimally supported extravascular device – Islet Sheet Medical & Cerco Medical	61
5.2.5.	Uncertain type of extravascular device – Gore Medical	61
5.2.6.	Mechanical extravascular device supplying oxygen to islets – Beta-O ₂	61
5.2.7.	Alginate micro-capsules – Connaught Laboratories and Damon Biotech	62
5.2.8.	Alginate micro-capsules to macro-devices to conformal coatings – Group of Cell Biotech, TransCell, Neocrin, Novocell, and Converge	62
5.2.9.	Hollow fibers and alginate micro-capsules – Biohybrid	62
5.2.10.	Alginate & PEG micro-capsules – Group of VivoRx and Amcyte	62
5.2.11.	Alginate micro-capsules – Group of TransTech, Metabolex, and Islet Tech	62
5.2.12.	Alginate micro-capsules – Living Cell Technologies	62
5.2.13.	Alginate micro-capsules – Micro-islet	62
5.2.14.	Hydrogel micro-capsule patch – Encapsulife	63
5.2.15.	Additional Patents that were licensed to different companies	63
6.	Summary of progress	63
7.	Critical needs required for clinical success	63
8.	Addendum	63
	Acknowledgments	63
	Appendix A. David W. Scharp, MD – Islet Encapsulation Corporate Experience	64
	References	65

1. Introduction

1.1. Historic antecedents to islet encapsulation

1.1.1. Diabetic antiquities

As an introduction to his MD Thesis in 1983 and in a later publication, Richard Downing has presented a well-studied history of diabetes and insulin-producing cell transplantation. It is summarized in part here to explain the important developments that resulted in islet encapsulation [1,2]. The signs of diabetes were described in clinical terms in antiquity starting with polyuria and polydipsia in the Ebers Papyrus dated 1500 B.C. [3] followed by Hippocrates (469–399 B.C.), Aristotle (384–322 B.C.), Celsus (30 B.C.–50 A.D.), and Galen (129–199 A.D.) [4,5]. Aretaeus the Cappadocian (30–90 A.D.) named the disease “diabetes” from the Greek word for “siphon” to describe the polydipsia and polyuria that are a clinical hallmark of that disease [4]. Polyuria was recognized in China in the third century but not recorded in writing as “sweet urine” until the seventh century [3,6]. An Indian physician described a sign of diabetes as “honey urine” in the fifth century [7]. The Arabian physician, Avicenna (980–1027 A.D.) was the first to describe complications of diabetes including gangrene [8]. Pathologic descriptions of glycosuria began with Paracelsus (1493–1541) and Willis (1621–1675) who also added the Latin word for honey, “mellitus”, to the name, diabetes [9]. Johan Frank differentiated diabetes

mellitus from diabetes insipidus in 1794 [9]. The French chemist Chevreul (1797–1889) showed that the sugar that spilled into the urine in diabetics was actually glucose [10]. While suggestions had been made that sugar may be elevated in the blood in patients with diabetes, it was Chauveau in 1856 who established that hyperglycemia was a hallmark of diabetes and critical in its diagnosis [11].

1.1.2. Clinical diabetes prior to insulin

The pancreas was first implicated in clinical diabetes in 1788 following an autopsy by Cawley of a 34 year old who had diabetes secondary to chronic pancreatitis [12]. Several reports of diabetes secondary to pancreatitis then followed by Bright in 1831, Bouchardat in 1875, and Lancereaux in 1877 [7,13,14]. Paul Langerhans first identified pancreatic islets during his thesis as a medical student in 1869 by careful evaluation of histologic sections of the pancreas observing isolated nests of small, clear cells scattered in the pancreas that he speculated might be lymph tissue [15]. The relationship of his findings to diabetes was not appreciated until suggested by Schafer in 1895 [16]. It was Opie in 1901 who first described hyaline degeneration of the islets in diabetic patients [17]. While Brunner had described the removal of the dog pancreas was followed by polyuria and polydipsia in 1682 [18], its importance was not understood until Mering and Minkowski reported a series of dog pancreatectomies in 1889 that defined diabetes as an absence of some function of the pancreas [19]. Then Laguesse in 1893

Download English Version:

<https://daneshyari.com/en/article/2070899>

Download Persian Version:

<https://daneshyari.com/article/2070899>

[Daneshyari.com](https://daneshyari.com)